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Abstract
Background: Toll-like receptor 4 (TLR4) is widely recognized as an essential element in the triggering of innate
immunity, binding pathogen-associated molecules such as Lipopolysaccharide (LPS), and in initiating a cascade of
pro-inflammatory events. Evidence for TLR4 expression in non-immune cells, including pancreatic b-cells, has been
shown, but, the functional role of TLR4 in the physiology of human pancreatic b-cells is still to be clearly
established. We investigated whether TLR4 is present in b-cells purified from freshly isolated human islets and
confirmed the results using MIN6 mouse insulinoma cells, by analyzing the effects of TLR4 expression on cell
viability and insulin homeostasis.
Results: CD11b positive macrophages were practically absent from isolated human islets obtained from non-
diabetic brain-dead donors, and TLR4 mRNA and cell surface expression were restricted to b-cells. A significant loss
of cell viability was observed in these b-cells indicating a possible relationship with TLR4 expression. Monitoring
gene expression in b-cells exposed for 48h to the prototypical TLR4 ligand LPS showed a concentration-dependent
increase in TLR4 and CD14 transcripts and decreased insulin content and secretion. TLR4-positive MIN6 cells were
also LPS-responsive, increasing TLR4 and CD14 mRNA levels and decreasing cell viability and insulin content.
Conclusions: Taken together, our data indicate a novel function for TLR4 as a molecule capable of altering
homeostasis of pancreatic b-cells.
Background
Islets are small organ-like structures, which are rich in
vasculature and are predominantly constituted of insu-
lin-secreting b-cells and glucagon-producing a-cells. As
the main target of autoimmunity that results in type 1
diabetes, b-cells have been the subject of numerous stu-
dies aiming to identify the mechanisms which cause the
massive cell death that ultimately leads to overt disease.
In the setting of autoimmunity, b-cells respond to the
onslaught of proinflammatory cytokines produced by
immune cells, such as interleukin (IL)-1b, tumor necro-
sis factor (TNF) -a and interferon- g,w h i c ht r i g g e rt h e
NF-B pathway and promote transcription of genes that
ultimately cause b-cell dysfunction and cell death [1].
A promising treatment for type 1 diabetes is islet cell
transplantation [2]. To this end, pancreata from brain-
dead non-diabetic donors are selected and islets are har-
vested and purified in clean room facilities for infusion
into the portal vein of diabetic patients. However, the iso-
lation procedure employed to obtain purified islets is
time-consuming and frequently fails to produce sufficient
good quality islets to enable a successful engraftment. The
low yield during the isolation procedure can be credited,
at least in part, to previously identified factors present in
the organ donors, such as: advanced age, cause of brain
death, episodes of anoxia, hypertension, use of vasopres-
sors, which cause ischemia, poor glycemic control, and
extended periods in the Intensive Care Unit [3,4]. In addi-
tion, studies in an experimental model showed that brain
death triggers an early increase in serum proinflammatory
cytokines, such as TNF-a, IL-1, and IL-6 and that their
transcription, together with that of the chemokine
* Correspondence: goldberg@einstein.br
1Núcleo de Terapia Celular e Molecular, Universidade de São Paulo, São
Paulo, Brasil
Full list of author information is available at the end of the article
Garay-Malpartida et al. BMC Immunology 2011, 12:18
http://www.biomedcentral.com/1471-2172/12/18
© 2011 Garay-Malpartida et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Monocyte Chemotactic Protein-1 (MCP-1), are increased
in the pancreas [5,6].
Inherent difficulties in separating islets from the sur-
rounding acinar tissue may also contribute to a lower
islet recovery [7-9], and a common feature resulting
from the isolation procedure will be a certain amount of
cell death and loss of insulin content; both being hall-
marks of low-quality harvested islets.
In the past two decades, Toll-like receptors (TLRs)
have been progressively acknowledged as crucial patho-
gen recognition receptors, playing major roles in innate
responses, as well as in triggering adaptive immunity
[10]. The manifold properties of TLRs have been mainly
identified in immune cells, especially macrophages and
dendritic cells [11]. The most extensively studied recep-
tor is TLR4, which is the receptor for Gram-negative
bacterial endotoxins, collectively known as LPS. Control
of TLR4 activation involves glycosylphosphatidylinositol
(GPI)-anchored CD14, MD-2, and the Lipopolysacchar-
ide-binding protein (LPB). LBP binds to the lipid A moi-
ety of LPS and transfers LPS to CD14, which guarantees
and optimizes signaling through the TLR4 complex [12].
Besides being found in antigen-presenting cells, several
TLRs, and more specifically, TLR4, have been identified
in other cell types, such as endothelial cells [13,14],
myocytes [15], thyroid cells [16], endometrial cells [17],
mesangial cells [18], and adipocytes [19]. In each of
these cases, TLRs participate in responses associated to
stress and disease. TLR4 has also been identified in
human b-cells and b-cell lines such as HP62 [20]. In
2003, using immunofluorescence-based methods, whole
islets and the SV40-transformed HP62 b-cell line were
shown to express TLR4 and CD14. However, the
expression was not restricted to b-cells, since glucagon-
secreting a-cells and even ductal cells were also positive.
In the present study, we investigated whether “ex-vivo”
expression of TLR4 occurs in b-cells from islets har-
vested from brain dead donors, and the effects of TLR4
activation on insulin production and secretion, and on
cell viability.
Results
Islets harvested from brain dead donors display variable
expression levels of TLR4
Analysis of gene expression at the mRNA level, by
quantitative RT-PCR, in freshly isolated human islets or
in non- adherent islet cultures, confirmed the presence
of TLR4 transcripts. In 11 out of 12 islet cell prepara-
tions, from different pancreata, analyzed immediately
after the isolation procedure, variable levels of TLR4
gene expression were observed, which persisted for up
to 48h in culture. No association was observed between
TLR4 expression levels and glucose-induced insulin
secretion in purified islets, cold ischemia time (time
lapse between organ procurement and the beginning of
the isolation procedure) or other donor variables, such
as donor age, days in the Intensive Care Unit or the pre-
sence of infection (data not shown). However, when the
relative mRNA expression was measured at 0, 24, and
48h, the Pearson coefficient test (-0.9 <r > 0.9, p < 0.05)
r e v e a l e dap o s i t i v ec o r r e l a tion between TLR4 and well
known pro-inflammatory molecules involved in b-cell
death, namely caspase-1, MCP-1, IL-1 receptor antago-
nist, and Fas (CD95) gene expression levels. This corre-
lation was particularly evident in pancreatic islets
obtained after low yield islet isolation procedures, in
which islets displayed low cell viability, as measured by
the live/dead fluorescence method, even though the
relative mRNA levels differed in islets from one pan-
creas to another (Table 1).
TLR4 expression observed on the surface of human
pancreatic islets is mainly restricted to b-cells
We then investigated whether the TLR4 gene expression
observed was restricted to functional endocrine islets
cells or due to infiltrating macrophages and dendritic
cells present within the islets.
To confirm which cell types were expressing the func-
tional TLR4 protein, triple staining with Newport Green
(NG), which is specific for Zn-rich insulin granules [21]
anti-TLR4-APC, and anti-CD11b-PE antibodies, was
performed for flow cytometric analysis in isolated cells
obtained after treatment with Accutase. As observed
with mRNA transcripts, islets showed variable levels of
TLR4 expression on the cell surface (11.3 ± 4% of total
cells, n = 3) (Figure 1a), which was almost exclusively
present in insulin-producing b-cells (84.7 ± 3% of
TLR4-positive cells) (Figure 1b). The percentage of
CD11b+ cells was very low, but consistently TLR4 posi-
tive (9.2 ± 2% of TLR4-positive cells) (Figure 1c). The
fact that macrophages are present in a very low number
is not surprising, considering that these islets were
obtained from non-diabetic donors and non-infected
pancreata, therefore, one would not expect to find infil-
trating leukocytes.
LPS-induced TLR4 expression in cultured b-cells leads to
loss of cell viability
To investigate whether TLR4 activation affects viability
of the pancreatic b-cells, the response of adherent cell
cultures to LPS was tested. Following a 48h exposure to
different concentrations of LPS (0, 5, and 50 ng/mL),
the islet cells showed a markedly enhanced mRNA
expression of both TLR4 and the LPS-associated CD14
molecules, in a concentration-dependent manner (Figure
2a-b). After 48h the cells were harvested and analyzed
by flow cytometry with anti-TLR4/NG/TMRE triple
staining. A significant reduction of cell viability was
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0.01) at 48h (Figure 3b), revealing the involvement of
the activated TLR4 signaling pathway in the mechanism
of b-cell death.
TLR4 expression is accompanied by decreased insulin
synthesis and secretion
Since a recently reported study indirectly associated
TLR4 to glucose-mediated ins u l i nr e g u l a t i o ni nh u m a n
peripheral blood monocytes [22], we hypothesized that
this receptor could also be operating a negative regula-
tory mechanism in pancreatic b-cell insulin production
and secretion.
As measured by NG-positive staining (Figure 4a), the
relative proportion of insulin content in LPS-treated
cells was reduced by 25.8 ± 6.5% (n = 7, p <0 . 0 0 1 ) ,
when compared with non-treated cells (Figure 4b).
Under the same conditions, we observed a discrete, but
significant, decrease of insulin mRNA expression (Figure
4c). In agreement with these data, a 43.5 ± 3.7% (n = 7,
p < 0.0001) decrease in insulin secretion was observed
in b-cells treated with LPS (Figure 4d).
The effects of LPS-induced TLR4 expression in mouse
MIN-6 cells closely resemble those observed in cultured
human islets
In order to confirm the effects of TLR4 activation in b-
cells, we assessed LPS-induced stimulation of TLR4
expression in MIN-6 mouse insulinoma cells. Under the
same conditions used for human islet adherent cell
Figure 1 Flow cytometric analysis of TLR4 expression in human islet cells. Free-floating 8-12 day islet cultures (500-1000 IEQ) were
dissociated into single-cell suspensions and assessed by flow cytometry. A representative image from three independent experiments is shown.
(a) Histogram compares total TLR4-positive cells (gray) with isotype-matched goat anti-rabbit IgG control for TLR4 staining (no color). (b) The
right upper quadrant of the dot plot shows the TLR4 positive b-cell population, double-stained for Newport Green (NG) and TLR4-APC
conjugate, (c) The right upper quadrant of the dot plot shows TLR4-positive macrophage-derived cells (non b-cells) double stained with TLR4-
APC conjugate and CD11b-PE conjugate, (d) Tetramethylrhodamine (TMRE) and NG double staining marks viable b-cells.
Table 1 Outcomes of islet isolation from pancreata used in this study
Pre-isolation Post-isolation
Isolation procedure Age Sex Glycemic levels Total IEQ
(1) Purity
(2) Viability
(3) TLR4 expression
(mg/dL) mRNA
(4) Correlation
(5)
PHum1 42 M 186 143,000 70% 80% Yes No
PHum2 52 F ND 116,000 80% 80% Yes No
PHum3 42 M 109 50,000 50% 70% Yes Yes
PHum4 41 M 149 73,000 70% 60% Yes No
PHum5 56 F 140 66,160 60% 50% Yes Yes
PHum6 55 M 143 204,458 90% 90% Yes No
PHum7 54 M 164 23,000 40% 40% Yes Yes
PHum8 53 F 113 60,000 70% 70% Yes Yes
PHum9 55 F 193 93,333 80% 80% Yes No
PHum10 35 M 162 555,125 90% 90% No No
PHum11 55 F 293 380,233 80% 90% Yes No
PHum12 49 F 93 48,000 60% 50% Yes Yes
(1) Each IEQ (islet equivalent) represents one islet 150 μm in diameter, (2) Purity is defined by percentage of Dithizone-positive cells (beta cells) in the islet
preparations, (3) Viability as measured by live/dead fluorescence, (4) Relative TLR4 mRNA expression levels are variable and this column indicates only presence
(Yes) or absence (No) of detectable levels of TLR4 mRNA at any time point, (5) Correlation was obtained from time-course analysis of mRNA expression of TLR4
and b-cell death-associated molecules by the Pearson coefficient test. The presence (Yes) or absence (No) corresponding to a significant positive or negative
linear correlation (-0.9 <r > 0.9, p > 0.05) is indicated in this column.
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TLR4 and CD14 mRNA levels, respectively (Figure 5a),
which were accompanied by a 35.9 ± 3% loss in cell via-
bility (n = 7, p < 0.001) in response to LPS (50 ng/mL)
in MIN-6 cells (Figure 5b-c). LPS was also capable of
inducing a strong reduction of insulin content (74.6 ±
4.2%, n = 3), as measured by NG-positive staining
(Figure 5d-e). Taken together, these data suggest that
the mechanisms for cell death and regulation of insulin
homeostasis can be modulated by TLR4 in human and
murine LPS-stimulated b-cells.
Discussion
In accordance with a growing literature showing that
Toll-like receptors exhibit functions in the homeostasis
of several types of non-immune cells [13-20], here we
show that b-cells harvested from human non-diabetic
brain-dead organ donors also express variable levels of
TLR4. Our results indicate that there could be a role for
TLR4 in b-cell homeostasis, possibly related to cell via-
bility or insulin production.
In contrast with a previous study [20], we showed that
LPS not only increases TLR4 expression and diminishes
cell viability, but, also, leads to loss of b-cell insulin con-
tent. In both non-diabetic human and murine b-cells,
TLR4 as well as CD14 transcripts were identified, with
LPS (50 ng/mL) leading to a concentration-dependent
increase in their gene expression levels, in parallel with
lowered cell viability and decreased insulin content and
mRNA transcription. These results are in agreement
with a study showing that blocking TLR4 expression in
murine islets by carbon monoxide treatment leads to
increased survival of islet implants in an allogenic mur-
ine model [23]
In a recent study [24] with the BRIN BD11 rat clonal
cell line, the authors showed decreased insulin secretion
Figure 3 Long-term exposure to LPS induces a loss of b-cell
viability. Under the same conditions described in the legend to
Figure 2, cell viability was analyzed by flow cytometry using TMRE
staining. (a) Histogram showing the percentage of TMRE-positive
cells upon treatment with 50 ng/mL LPS (red line), untreated
control cells (green line) and isotype-matched control for TLR4
staining (dotted black line). (b) Values represent the relative
percentage of TMRE-positive b-cells. Data are expressed as mean ±
SD for b-cell cultures derived from different pancreas donors (n =
7), incubated with or without LPS 50 ng/mL for 48 h and analyzed
in triplicate. Statistically significant differences are indicated as (**) p
< 0.005, compared to non-treated control cells.
Figure 2 LPS-induced TLR4 expression in b-cells.5×1 0
5 human
b-cells from adherent cultures were treated with LPS (5 and 50 ng/
mL) and analyzed after 48 h. Expression of (a) TLR4 and (b) CD14
mRNA is shown as mean ± SD (3 independent experiments) of
relative fold increase in gene expression at 48 h, compared to
control (untreated) cells. Statistically significant differences are
shown as (*) p < 0.05 and (**) p < 0.005.
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insulin content. The authors also observed a reversal of
the effect on insulin secretion upon removal of LPS.
The observed lack of change in insulin content may be
explained by the fact that cells were incubated with 100
ng/mL LPS only for 24h, in contrast to our incubation
period for up to 48h, but using half the dose of LPS.
Indeed, in our study, we also observed a low effect upon
insulin content when cells were incubated for 24h (data
not shown). Taken together, these findings suggest that
effects on b-cell insulin content and cell viability require
more time to take place.
In addition to the classical activation, via pathogen-
associated molecular patterns, TLR expression in mono-
cytes has been shown to be regulated by glucose [22].
High glucose levels induced TLR2 and TLR4 expression
while Mannitol did not, excluding an osmotic effect as
the cause for observed results. Increased TLR4 expres-
sion occurred due to PKC-δ-mediated activation and sti-
mulated p47Phox-dependent NADPH oxidase activity,
establishing a link between high glucose, NF-B-
mediated inflammatory cytokine production, and TLR
expression. In another study, with type 2 diabetic
patients, in which TLR expression in mononuclear cells
was monitored in response to low-dose insulin infusion,
a further relationship between TLR2 and TLR4, and
insulin homeostasis was identified [25]. Steady-state
infusion during a short 4h period caused an increase of
approximately 2.5 fold in insulin plasma levels while
maintaining the patient’s glycemia, and led to decreased
TLR expression, which occurred independently of blood
glucose levels. The effect of this short-term experiment,
however, was more pronounced on TLR2 than on TLR4
expression. It is possible that increasing the period of
Figure 5 Effects of LPS on TLR4 expression, cell viability and
insulin synthesis in murine insulinoma cells.5×1 0
5 MIN-6 cells
treated with LPS (50 ng/mL) were analyzed after 48 h for gene
expression, cell viability and insulin production. (a) TLR4 and CD14
mRNA expression is shown as mean ± SD (n = 3) of relative fold
increase compared to control (untreated) cells. Representative flow
cytometry histogram of (b) percent TMRE-positive or (d) percent
NG-positive cells treated with LPS (red line), untreated or control
cells (green line) and isotype-matched control for TLR4 staining
(dotted black line). Relative percentage of (c) TMRE positive or (e)
NG positive cells expressed as mean ± SD (n = 3). In all cases,
statistically significant differences are indicated as (*) p < 0.05 and
(**) p < 0.005, compared to non-treated control cells.
Figure 4 Effects of LPS treatment on insulin synthesis and
secretion by b-cells. After 48 h of LPS stimulation, the effects on
insulin homeostasis were measured by flow cytometry. (a)
Representative histogram of percent NG-positive cells after
treatment with LPS (red line), untreated or control cells (green line)
and isotype-matched controls for the TLR4 staining (dotted black
line). Data represent relative percentage of (b) NG-positive cells
compared to control cells, expressed as mean ± SD for several b-
cell cultures derived from different pancreas donors (n = 7), and
analyzed in triplicate. (c) Insulin mRNA expression is shown as mean
± SD (3 independent experiments) of relative fold increase
compared to control (untreated) cells. (d) Insulin secretion
measured by chemiluminescence in b-cell cultures isolated from
two different pancreata expressed as relative percentage of insulin
secretion observed in control cells, and analyzed in triplicate (mean
± SD). Statistically significant differences are indicated as (**) p <
0.005, as compared to non-treated control cells.
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expression.
Our study suggests a further link between insulin
homeostasis, cell viability, and TLR4 expression.
Although we did not measure apoptosis-related mole-
cules, we used TMRE as an indirect marker for apopto-
sis. TMRE is a dye with a high degree of membrane
permeability that accumulates in viable mitochondria,
thereby marking only cells that are not undergoing
apoptosis. In the presence of LPS-induced TLR4 expres-
sion, in both human and murine b-cells, insulin mRNA,
insulin secretion and insulin content were diminished,
and b-cell viability was decreased (from 100 to approxi-
mately 60%, Figure 3b).
Endogenous ligands for TLR4 have been described,
most of which have been proven to exert their effect
independently of an eventual experimental LPS contami-
nation [26]. The list includes heat shock proteins 60 and
gp96 [27,28], fibronectin type III extra domain A [29],
hyaluronan [30], saturated fatty acids [15], advanced gly-
cation end-products [31] and heme [32]. In other words,
molecules produced or circulating during abnormal
situations such as tissue damage and ischemia are cap-
able of triggering TLR4- dependent pathways. These
conditions are commonly present in brain-dead organ
donors, being potential causes of engraftment failure as
well as setting the conditions for inappropriate expres-
sion of TLR4 on non-immune cells. It remains to be
seen how many of these potentially damaging factors
are present before and during the long-lasting islet isola-
tion procedures, and which, by favoring TLR4 expres-
sion, may further contribute to diminished insulin
content and lower islet yield.
We can also envisage that increased glucose plasma
levels not only induce insulin secretion, triggering insu-
lin gene transcription and replacement of the intracellu-
lar stocks, but also increase surface expression of TLR4
molecules. The release of endogenous TLR4 ligands
during tissue damage and inflammation followed by
docking onto b-cells, could then result in loss of the
ability of these b-cells to respond normally to glucose,
contributing to the extra load of circulating plasma glu-
cose and worsening of the glycemia control observed in
response to TNF-a and adrenalin, as well as other hor-
mones secreted under stressful situations.
Conclusion
In conclusion, in the present study, we not only confirm
the expression of TLR4 in pancreatic b-cells, but also
suggest that its expression impacts upon b-cell viability
and insulin synthesis and secretion, indicating that
TLR4 should be included in the list of molecules affect-
ing control of insulin homeostasis in b-cells.
Methods
Islet isolation and primary cell culture
Pancreata were removed from adult non-diabetic
brain-dead donors (mean age 54 ± 5 years, n = 12)
after in situ vascular perfusion with cold University of
Wisconsin (UW) solution, in accordance with Brazilian
regulations. The clinical trials were cleared by the local
Institutional Ethics Committees at Universidade de São
Paulo and Hospital Israelita Albert Einstein, Approval
from the Brazilian National Ethical Committee
(CONEP http://conselho.saude.gov.br/web_comissoes/
conep/index.html) for pancreas procurement and
human pancreatic islet isolation is registered under n°
4506. Pancreatic islets were isolated after ductal disten-
sion of the pancreas and tissue digestion with Liberase
H1 (Roche Diagnostics, Indianapolis, IN) according to
the automated method of Ricordi et al. [33]. Islet pre-
parations exhibited 60-90% purity as determined by
Dithizone staining. Islet cell viability was evaluated by
the live/dead fluorescence, based on incorporation of
either acridine orange by live cells or propidium iodide
by dead cells, being usually greater than 60%. Upon
isolation, islets were maintained in free-floating condi-
tions in non-adherent T75 flasks with CMRL 1066
medium (Mediatech-Cellgro, Miami, FL) supplemented
with 20% human albumin, 100 mM sodium piruvate,
30 mM vitamin E, 2.5 mM nicotinamide, and 0.2%
ciprofloxacin. All cultures were maintained at 37°C,
and 5% CO2 in a humidified incubator. Part of the
islet preparation, that is 3000-5000 islet equivalents
(IEQ), which correspond to approximately 3 × 10
5
cells/mL, was kept in non-adherent flasks and cultured,
as described above, during 8-12 days. The remaining
islets were transferred to T75 adherent culture flasks
and grown in CMRL 1066 supplemented with 100
units/mL penicillin and 5% of fetal calf serum (FCS).
After spontaneous dissociation with a 1g/L trypsin
solution (Life Technologies Inc., Grand Island, NY) for
1 min at room temperature, 5 × 10
5 cells/well were
plated in 6-well adherent dishes. At 70-80% conflu-
ence, cells were treated with the indicated concentra-
tions of LPS 0-50 ng/mL (Ctlg # 62326, Sigma-Aldrich,
IL) during 48 h. All human cell cultures were main-
tained in the absence of FCS to avoid interference
from collected medium in the insulin measurements.
Murine cell line
MIN-6 mouse insulinoma cells (a gift from Professor A.
C. Boschero, UNICAMP, Campinas, Brazil) were cul-
tured at 37°C in RPMI medium containing 5.6 mM glu-
cose, 10% FCS, 100 U/mL penicillin, and 100 μg/mL
streptomycin in a humidified atmosphere with 5% CO2.
For the assays, 5 × 10
5 cells were plated per well in
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treated with the indicated concentrations of LPS (0-50
ng/mL) for different periods of time (0-48 h) with only
a minimum (0.5%) of FBS added.
Flow cytometry
Islets from free-floating cell cultures (500-1000 IEQ)
were harvested by centrifugation at 280g for 5 min at
4°C, and dissociated into single-cell suspensions by
treatment with Accutase (Innovative Cell Technologies,
Temecula, CA) for 10-12 min at 37°C as previously
described [34]. Adherent islet cells and MIN6 cell cul-
tures were dissociated with a 1g/L trypsin solution for
1min at room temperature. In all cases, single cells were
harvested by centrifugation (280 × g for 5 min at 4°C),
washed twice with PBS and filtered through a 0.70 μm
mesh nylon filter. Cells were resuspended in PBS at a
concentration of 10
7 cells/mL and aliquots (10
4 cells/μl)
were transferred to FACS tubes. To stain insulin posi-
tive cells, we used 1 μM Newport Green (NG) in PBS
(Newport Green PDX
® acetoxymethyl ether, Molecular
Probes, Eugene, OR). Cell viability was measured with
Tetramethylrhodamine (TMRE) 100 nM (Molecular
Probes, Eugene, OR) staining. In both assays, cells were
incubated during 1 h at 37°C in the dark. To discrimi-
nate TLR4-positive viable b-cells, a triple staining with
anti-TLR4-APC conjugate (eBioscience, San Diego, CA),
NG and TMRE was performed during 15 min at 37°C,
in the dark. TLR4-positive immune cells were identified
by triple staining, achieved under the same conditions,
but using anti-TLR4-APC conjugate, NG and anti-
CD11b-PE conjugate (BD Biosciences, San Jose, CA).
Stained cells (10,000-20,000 cells/sample) were analyzed
with a FACSCalibur flow cytometer, using the CellQuest
program (BD Biosciences, San Jose, CA). Unstained cells
(auto-fluorescence) or goat anti-rabbit IgG (isotype-
matched) were used as reference controls for each
experiment. Data were analyzed with WinMDI software
(Scripps, La Jolla, CA).
Real-time quantitative RT-PCR (qRT-PCR)
Total RNA from 1,000-2,000 IEQ was extracted using
Trizol
® reagent (Invitrogen, San Diego, CA), according
to the manufacturer’s instructions, and cDNA was
synthesized from 2 μg of total RNA using SuperScript™
III Reverse Transcriptase kit (Invitrogen, San Diego, CA)
with oligo dT primers. Real-time PCR was performed
according to the Sybr
®Green assay protocol (Applied
Biosystems, Foster City, CA), using the Sequence Detec-
tor ABI PRISM 7500 (Perkin-Elmer/Applied Biosystems,
Foster City, CA, USA). The gene-specific PCR primers
were designed to span an intron with Primer3
® software
(sequences available upon request). We used a 2-step
amplification protocol with a denaturing temperature of
95°C and an annealing-extension temperature of 60°C.
The relative gene expression was calculated from cycle
threshold values (Ct) using the Pfaffl method [35].
Human or murine HPRT gene expression was used as an
internal reference for each individual sample.
Cumulative insulin secretion
Conditioned medium from cultures incubated for 48h in
t h ep r e s e n c eo ri nt h ea b s e n c eo f5 0n g / m LL P Sw a s
collected and accumulated insulin release was quantified
by the ELECSYS chemiluminescence assay, according to
the manufacturer instructions (Roche Diagnostics, India-
n a p o l i s ,I N ) .R e s u l t sw e r en o rmalized by total protein
quantified by the Bradford method.
Statistical analysis
Data are presented as the mean ± standard deviation
(SD). Each experiment was repeated at least three times
with triplicate values within each group. Differences
between means were analyzed by Student’stt e s t .Ap
value < 0.05 was considered statistically significant. Ana-
lyses were performed using the Prism software version
4.0 (Graph Pad Software Inc., San Diego, CA).
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